The Lumipulse Alzheimer’s blood test is highly accurate for estimating whether a person with cognitive symptoms has brain amyloid pathology, but its three result categories do not carry equal certainty. In the FDA-reviewed study, 91.7% of people with a positive result were amyloid-positive on PET imaging or cerebrospinal fluid testing, while 97.3% of those with a negative result were amyloid-negative. For example, a positive result strongly supports the presence of amyloid plaques, but it does not by itself prove that Alzheimer’s disease is causing the person’s memory problems. An indeterminate result is deliberately less decisive.
In the study of 499 cognitively impaired adults, 98 received an indeterminate result; exactly half were amyloid-positive on the reference test and half were amyloid-negative. This middle category helps reduce false positive and false negative classifications, but it usually means the person needs amyloid PET imaging, cerebrospinal fluid analysis, or further specialist evaluation. The test measures plasma phosphorylated tau 217, or p-tau217, and beta-amyloid 1-42, then calculates their ratio. It is intended as an aid for evaluating adults age 50 and older who have signs or symptoms of cognitive decline in a specialized care setting. It is not intended as general screening for people without symptoms or as a stand-alone diagnosis.
Medical information disclaimer: This article is for general educational purposes only and does not provide medical advice, diagnosis, or treatment. Always consult a physician or other qualified health professional about symptoms, medications, tests, or treatment decisions.
Table of Contents
- How Accurate Are Positive, Negative, and Indeterminate Lumipulse Alzheimer’s Blood Test Results?
- What a Positive Lumipulse p-Tau217/Amyloid Result Actually Means
- Understanding a Negative Lumipulse Alzheimer’s Blood Test
- What to Do After Each Lumipulse Test Result
- False Results, Borderline Values, and Laboratory Limitations
- Why Lumipulse Uses a Three-Range System
- How Amyloid Status Fits Into a Dementia Evaluation
- Frequently Asked Questions
How Accurate Are Positive, Negative, and Indeterminate Lumipulse Alzheimer’s Blood Test Results?
A Lumipulse ratio of 0.00738 or higher is classified as positive. Among the 219 positive results in the FDA-reviewed clinical study, 201 agreed with an amyloid-positive PET scan or cerebrospinal fluid result. That produced a positive predictive value of 91.8% in the study population. Put another way, roughly eight of every 100 positive results did not match the amyloid reference assessment. A ratio of 0.00370 or lower is classified as negative.
Of the 182 people in this category, 177 were amyloid-negative on the reference assessment, corresponding to a negative predictive value of 97.3%. A negative result therefore provides strong evidence against significant amyloid pathology at that time, although five people in the study had amyloid pathology despite being classified as negative. Ratios from 0.00371 through 0.00737 are indeterminate. This is not a mildly positive diagnosis or a laboratory error; it means the measured ratio lies in a zone where the blood test cannot separate amyloid-positive from amyloid-negative cases reliably. In the FDA decision summary, 49 of the 98 indeterminate cases were amyloid-positive and 49 were amyloid-negative.
What a Positive Lumipulse p-Tau217/Amyloid Result Actually Means
A positive result means the blood biomarker pattern is consistent with amyloid plaques associated with Alzheimer’s disease. Amyloid is an important biological feature of the disease, and identifying it can help a specialist decide whether Alzheimer’s is a likely contributor to cognitive decline. The result may also help determine whether more definitive testing is warranted when treatment decisions depend on confirmed amyloid pathology. A positive blood result is not equivalent to a complete Alzheimer’s diagnosis.
Some people have amyloid plaques without dementia, while others have mixed disease involving Alzheimer’s pathology, vascular brain injury, Lewy body disease, or another condition. A 72-year-old with worsening short-term memory, a positive Lumipulse result, and an MRI showing several strokes may have more than one cause of impairment. False positives remain possible and can lead to distress, inappropriate labeling, or unnecessary treatment. The FDA specifically warns that the test must be interpreted with the clinical history and other diagnostic information. Cognitive testing, medication review, neurological examination, laboratory studies, and brain imaging remain important even when the blood result is positive.
Understanding a Negative Lumipulse Alzheimer’s Blood Test
A negative Lumipulse result means amyloid pathology is unlikely, not impossible. In the FDA-reviewed study, 2.7% of people with a negative result were amyloid-positive on PET or cerebrospinal fluid testing. The result is therefore reassuring when the person’s symptoms and examination also point away from Alzheimer’s disease, but it should not automatically end an evaluation. Consider someone whose blood test is negative but whose confusion began after a medication change.
The clinician may focus on sedating drugs, thyroid disease, vitamin B12 deficiency, sleep apnea, depression, seizures, or another potentially treatable explanation. A negative amyloid result does not mean the symptoms are imaginary or that no neurological disorder is present. Further amyloid testing may still be reasonable when the clinical picture strongly suggests Alzheimer’s disease, symptoms are progressing, or a treatment decision requires greater certainty. False negative results can delay an accurate diagnosis, particularly if the blood result is allowed to outweigh a detailed history and documented cognitive decline.
What to Do After Each Lumipulse Test Result
After a positive result, the ordering clinician should interpret it alongside the person’s symptoms, level of impairment, MRI findings, and cognitive testing. PET imaging or cerebrospinal fluid analysis may be considered if definitive amyloid confirmation is required before disease-modifying therapy. The tradeoff is that these tests can provide stronger confirmation but are more expensive, less accessible, or more invasive than a blood draw. After a negative result, attention often shifts toward other causes of cognitive impairment.
Depending on the situation, that may include blood tests, medication changes, sleep evaluation, MRI, or assessment for vascular, frontotemporal, or Lewy body disease. A specialist may still order amyloid PET or cerebrospinal fluid testing when the negative result conflicts with the clinical evidence. An indeterminate result generally calls for discussion of confirmatory testing rather than simply repeating the same interpretation. PET provides an image-based assessment of brain amyloid but involves a radioactive tracer and limited availability. A lumbar puncture can measure Alzheimer’s biomarkers in cerebrospinal fluid without radiation, although it is invasive and can cause a temporary headache.
False Results, Borderline Values, and Laboratory Limitations
Predictive accuracy depends partly on who is tested. The FDA performance study involved cognitively impaired adults evaluated in specialized settings, where 51.1% were amyloid-positive by PET or cerebrospinal fluid testing. Positive and negative predictive values may differ in a primary-care population, among people without symptoms, or in a group with a much lower prevalence of amyloid pathology. Values close to a cutoff deserve particular care.
Laboratories have warned that lot-to-lot assay differences could potentially move a result near 0.00370 from negative into the indeterminate range. A clinician reviewing a borderline value should examine the numerical ratio, not merely the word printed beside it, and ask whether the result fits the person’s symptoms and other findings. Laboratory quality issues can also affect classification. An FDA Class II recall initiated in December 2025 covered Lumipulse reagent lots D8C6022U and D8C6044U because affected testing could produce falsely elevated positive or indeterminate ratios. A person concerned about a result generated during the affected period can ask the laboratory whether either recalled lot was used and whether the result requires review or repeat testing.
Why Lumipulse Uses a Three-Range System
Using separate positive and negative thresholds creates a gray zone between them. This approach leaves some patients without an immediate answer, but it reduces the pressure to force borderline measurements into a potentially incorrect positive or negative category.
A single-cutoff test would classify everyone, although more people near that cutoff could be placed on the wrong side. In the FDA-reviewed study, 19.6% of participants landed in the indeterminate range. For a memory clinic evaluating 100 people similar to those studied, that rate would translate to about 20 people needing additional clarification rather than receiving a confident blood-based classification.
How Amyloid Status Fits Into a Dementia Evaluation
Amyloid status answers a biological question: whether evidence of amyloid plaque pathology is present. It does not establish the severity of cognitive impairment, identify every contributing disease, or show how quickly symptoms will progress. Those questions require a broader evaluation that may include reports from family members, standardized cognitive testing, functional assessment, neurological examination, and structural brain imaging.
For example, two people can both receive positive Lumipulse results while having very different clinical situations. One may have mild cognitive impairment and remain independent with finances and medications; the other may have dementia requiring daily supervision. The same positive amyloid classification does not make their care needs, treatment risks, or expected course identical.
Frequently Asked Questions
Does a positive Lumipulse blood test confirm Alzheimer’s disease?
No. It strongly supports the presence of amyloid pathology associated with Alzheimer’s disease, but diagnosis also requires clinical evaluation and consideration of other causes of cognitive decline.
How reliable is a negative Lumipulse result?
In the FDA-reviewed study, 97.3% of people with negative results were amyloid-negative on PET imaging or cerebrospinal fluid testing. False negative results still occurred.
Is an indeterminate result closer to positive or negative?
Not necessarily. In the clinical study, the indeterminate group was evenly divided: 49 people were amyloid-positive and 49 were amyloid-negative on reference testing.
Should an indeterminate test simply be repeated?
The appropriate next step depends on the numerical value, laboratory considerations, symptoms, and reason for testing. A specialist may recommend amyloid PET imaging or cerebrospinal fluid analysis rather than relying on another blood result.
Can the Lumipulse test be used to screen a healthy person?
The FDA-cleared use is for adults age 50 and older with signs or symptoms of cognitive decline who are being evaluated in a specialized care setting. It is not intended as general population screening.
